Diabetes Research and Clinical Practice
Volume 61, Supplement 1 , Pages S9-S18, July 2003

Pre-diabetes, insulin resistance, inflammation and CVD risk

Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, DTL, Room 5.606U, Mail code 7873, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA

Abstract 

There is accumulating evidence that insulin resistance in the pre-diabetic state is associated with the presence of additional cardiovascular risk factors and increased incidence of cardiovascular disease (CVD). There is also accumulating evidence indicating that chronic sub-clinical inflammation as measured by such inflammatory markers as C-reactive protein (CRP) is associated with insulin resistance and other features of the insulin resistance syndrome, increased risk of development of type 2 diabetes and increased cardiovascular event risk. Insulin-sensitizing agents may have greater effects in reducing cardiovascular risk than secretagogues in the pre-diabetic state, and glitazones have been found to decrease CRP levels in patients with diabetes. Statins also reduce CRP levels. Efforts to reduce CVD should include increased emphasis on improving glycaemic control, preventing development of diabetes and addressing cardiovascular risk factors in the pre-diabetic state.

Keywords: Insulin resistance, C-reactive protein, Pre-diabetes, Diabetes, Statins

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8227(03)00122-0

doi:10.1016/S0168-8227(03)00122-0

Diabetes Research and Clinical Practice
Volume 61, Supplement 1 , Pages S9-S18, July 2003